Targeting the bone marrow microenvironment in multiple myeloma

TPL2 kinase regulates the inflammatory milieu of the myeloma niche

(2014) C. Hope et al.   BLOOD

Increased Regulatory versus Effector T Cell Development Is Associated with Thymus Atrophy in Mouse Models of Multiple Myeloma

(2014) A. Laronne-Bar-On et al.   JOURNAL OF IMMUNOLOGY

Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF- 1

(2014) H. Li et al.   JOURNAL OF IMMUNOLOGY

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib

(2014) A Ray et al.   LEUKEMIA

Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma

(2014) James Favaloro et al.   LEUKEMIA & LYMPHOMA

Engineered nanomedicine for myeloma and bone microenvironment targeting

(2014) A. Swami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Immune Suppression with PDE5 Inhibition in End-Stage Multiple Myeloma

(2014) K. A. Noonan et al.   Cancer Immunology Research

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells

(2013) T. Tanno et al.   BLOOD

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

Tumour-associated macrophages and cancer

(2013) Jenny Cook et al.   CURRENT OPINION IN PHARMACOLOGY

Macrophages in multiple myeloma

(2013) Domenico Ribatti et al.   IMMUNOLOGY LETTERS

BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression

(2013) Aldo M. Roccaro et al.   JOURNAL OF CLINICAL INVESTIGATION

Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma

(2013) T. J. Kearl et al.   JOURNAL OF IMMUNOLOGY

Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow

(2013) I. R. Ramachandran et al.   JOURNAL OF IMMUNOLOGY

Extracellular Matrix Remodeling by Bone Marrow Fibroblast-like Cells Correlates with Disease Progression in Multiple Myeloma

(2013) Astrid Slany et al.   JOURNAL OF PROTEOME RESEARCH

Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro

(2013) J. Hu et al.   MOLECULAR CANCER THERAPEUTICS

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment

(2013) Simona Berardi et al.   Journal of Oncology

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features

(2012) A. K. Azab et al.   BLOOD

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

(2012) Y.-T. Tai et al.   BLOOD

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

(2012) M. Chesi et al.   BLOOD

Myeloma as a model for the process of metastasis: implications for therapy

(2012) I. M. Ghobrial   BLOOD

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma

(2012) K Giannopoulos et al.   BRITISH JOURNAL OF CANCER

Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells

(2012) Jaehyup Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells

(2012) J. Faget et al.   CANCER RESEARCH

Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma

(2012) J. Corre et al.   CANCER RESEARCH

Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells

(2012) C. Conrad et al.   CANCER RESEARCH

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB

(2012) Stuart A. Rushworth et al.   CELLULAR SIGNALLING

Antiangiogenic Therapeutic Approaches in Multiple Myeloma

(2012) Domenico Ribatti et al.   CURRENT CANCER DRUG TARGETS

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry

(2012) R. J. Pessoa de Magalhaes et al.   HAEMATOLOGICA

Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells

(2012) R. N. Ramos et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

(2012) H Tamura et al.   LEUKEMIA

PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma

(2012) Y Zheng et al.   LEUKEMIA

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent

(2012) Sylvia Feyler et al.   PLoS One

Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma

(2012) Karthick Raja Muthu Raja et al.   PLoS One

Osteoclasts in Multiple Myeloma Are Derived from Gr-1+CD11b+Myeloid-Derived Suppressor Cells

(2012) Junling Zhuang et al.   PLoS One

Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade

(2011) William H.D. Hallett et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells

(2011) S. Solito et al.   BLOOD

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

(2011) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma

(2011) S K Martin et al.   LEUKEMIA

Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression

(2011) Mu Hao et al.   LEUKEMIA & LYMPHOMA

Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets

(2011) S Berardi et al.   ONCOGENE

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model

(2011) C. Meyer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

(2010) J. Hu et al.   BLOOD

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Chemoimmunotherapy Reduces the Progression of Multiple Myeloma in a Mouse Model

(2010) A. Sharabi et al.   Cancer Prevention Research

Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma

(2010) K. Klages et al.   CANCER RESEARCH

Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth

(2010) M. W. L. Teng et al.   CANCER RESEARCH

Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study

(2010) D. Ribatti et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

(2010) R A Kyle et al.   LEUKEMIA

Significantly reduced regulatory T cell population in patients with untreated multiple myeloma

(2010) Ritu Gupta et al.   LEUKEMIA RESEARCH

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

(2010) Stephanie Markovina et al.   Molecular Cancer

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

(2010) Douglas W McMillin et al.   NATURE MEDICINE

Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma

(2010) Xinhua Liang et al.   ORAL ONCOLOGY

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

(2010) M. K. Brimnes et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Bone Marrow Stromal Cells From Myeloma Patients Support the Growth of Myeloma Stem Cells

(2010) Yongdong Feng et al.   STEM CELLS AND DEVELOPMENT

Epithelial–Mesenchymal Transition: From Molecular Mechanisms, Redox Regulation to Implications in Human Health and Disease

(2009) Stefania Cannito et al.   ANTIOXIDANTS & REDOX SIGNALING

Induction of angiogenesis by normal and malignant plasma cells

(2009) D. Hose et al.   BLOOD

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

(2009) A. K. Azab et al.   BLOOD

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

(2009) M. Fulciniti et al.   BLOOD

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

(2009) Y. Zheng et al.   BLOOD

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

(2009) M Lioznov et al.   BONE MARROW TRANSPLANTATION

HIF-1α determines the metastatic potential of gastric cancer cells

(2009) N Rohwer et al.   BRITISH JOURNAL OF CANCER

CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden

(2009) Sylvia Feyler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked

(2009) Marie von Lilienfeld-Toal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma

(2009) Sarah Deleu et al.   CANCER RESEARCH

Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma

(2009) R. Ria et al.   CLINICAL CANCER RESEARCH

Prognostic significance of hypoxia-inducible factor-1 , TWIST1 and Snail expression in resectable non-small cell lung cancer

(2009) J-J Hung et al.   THORAX

Pathogenesis and management of myeloma bone disease

(2009) Dimitrios Christoulas et al.   Expert Review of Hematology

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

(2008) K. Movahedi et al.   BLOOD

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

(2008) Christine Galustian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells

(2008) P. Serafini et al.   CANCER RESEARCH

Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals

(2008) Masahiro Shinohara et al.   CELL

Pathogenesis of myeloma bone disease

(2008) G D Roodman   LEUKEMIA

The tumor microenvironment and its role in promoting tumor growth

(2008) T L Whiteside   ONCOGENE

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

(2008) M. Jinushi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA